Cancer biology and hormesis: Human tumor cell lines commonly display hormetic (biphasic) dose responses

被引:143
作者
Calabrese, EJ [1 ]
机构
[1] Univ Massachusetts, Amherst, MA 01003 USA
关键词
adaptation; antiestrogens; antineoplastic; biphasic; cancer; carcinogenesis; cell proliferation; chemotherapeutics; chemotherapy; estrogen; hormesis; low doses; mechanism; metals; phytochemical; tumor cell lines; U-shaped;
D O I
10.1080/10408440591034502
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
This article assesses the nature of the dose-response relationship of human tumor Cell lines with a wide range of agents including antineoplastics, toxic substances (i.e., environmental pollutants), nonneoplastic drugs, endogenous agonists, and phyto-compounds. Hormetic-like biphasic dose responses were commonly reported and demonstrated in 136 tumor Cell lines from over 30 tissue types for over 120 different agents. Quantitative features of these hormetic dose responses were similar, regardless of tumor cell line or agent tested. That is, the magnitude of the responses was generally modest, with maximum stimulatory responses typically not greater than twice the control, while the width of the stimulatory concentration range was usually less than 100-fold. Particular attention was directed to possible molecular mechanisms of the biphasic nature of the dose response, as well as clinical implications in which a low concentration of chemotherapeutic agent may stimulate tumor cell proliferation. Finally, these findings further support the conclusion that hormetic dose responses are broadly generalizable, being independent of biological model, endpoint measured, and stressor agent, and represent a basic feature of biological responsiveness to chemical and physical stressors.
引用
收藏
页码:463 / 582
页数:120
相关论文
共 271 条
[41]   Chemical hormesis: its historical foundations as a biological hypothesis [J].
Calabrese, EJ ;
Baldwin, LA .
HUMAN & EXPERIMENTAL TOXICOLOGY, 2000, 19 (01) :2-31
[42]   The marginalization of hormesis [J].
Calabrese, EJ ;
Baldwin, LA .
HUMAN & EXPERIMENTAL TOXICOLOGY, 2000, 19 (01) :32-40
[43]  
CALABRESE EJ, 2004, NONL DOS RESP C U MA
[44]  
Camby I, 1996, IN VITRO CELL DEV-AN, V32, P633
[45]  
Campbell MJ, 2002, ANTICANCER RES, V22, P3843
[46]   SURAMIN, AN EXPERIMENTAL CHEMOTHERAPEUTIC DRUG, ACTIVATES THE RECEPTOR FOR EPIDERMAL GROWTH-FACTOR AND PROMOTES GROWTH OF CERTAIN MALIGNANT-CELLS [J].
CARDINALI, M ;
SARTOR, O ;
ROBBINS, KC .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (04) :1242-1247
[47]   RELATIONSHIP BETWEEN THE MAP KINASE-ACTIVITY AND THE DUAL EFFECT OF EGF ON A431 CELL-PROLIFERATION [J].
CHAJRY, N ;
MARTIN, PM ;
PAGES, G ;
COCHET, C ;
AFDEL, K ;
BERTHOIS, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 203 (02) :984-990
[48]   Regulation of p42 mitogen-activated-protein kinase activity by protein phosphatase 2A under conditions of growth inhibition by epidermal growth factor in A431 cells [J].
Chajry, N ;
Martin, PM ;
Cochet, C ;
Berthois, Y .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 235 (1-2) :97-102
[49]   Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation [J].
Chan, CMW ;
Martin, LA ;
Johnston, SRD ;
Ali, S ;
Dowsett, M .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2002, 81 (4-5) :333-341
[50]   Induction of apoptosis in prostate cancer cell lines by a flavonoid, baicalin [J].
Chan, FL ;
Choi, HL ;
Chen, ZY ;
Chan, PSF ;
Huang, Y .
CANCER LETTERS, 2000, 160 (02) :219-228